STOCK MARKET BSE NSE

First COVID nasal vaccine by Bharat Biotech gets regulator's nod for holding phase 2, 3 clinical trials

Phase 1 clinical trial has been completed in age groups ranging from 18 to 60 years, the Department of Biotechnology said.

Published: 13th August 2021 06:43 PM  |   Last Updated: 13th August 2021 06:43 PM   |  A+A-

A health worker takes a nasal swab sample of an Indian police man in plain clothes to test for COVID-19 inside a park in Srinagar. (Photo | AP)

By PTI

NEW DELHI: The first nasal vaccine against COVID-19, developed by Bharat Biotech, has received regulator's nod for conducting phase 2 and 3 clinical trials, the Department of Biotechnology said on Friday.

Phase 1 clinical trial has been completed in age groups ranging from 18 to 60 years, it said.

ALSO READ | India's drug regulator approves study on mixing of Covaxin and Covishield doses

"Bharat Biotech's intranasal vaccine is the first nasal vaccine that has received the regulatory approval for Phase 2/3 trials," the DBT said.

This is the first of its kind COVID-19 jab to undergo human clinical trials in India.

BBV154 is an intranasal replication-deficient chimpanzee adenovirus SARS-CoV-2 vectored vaccine.

Bharat Biotech has in-licensed technology from Washington University in St Louis, US.

ALSO WATCH:



Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp